DGAP-News: Nanostart to feature successful completion of MagForce clinical trials at investor presentation in New York City

Nanostart AG / Miscellaneous 

04.11.2009 

Dissemination of a Corporate News, transmitted by 
DGAP - a company of EquityStory AG. 
The issuer / publisher is solely responsible for the content of this announcement. 
 

- Exclusive event for 80 specially invited guests 
- Highlight: Clinical efficacy of Nano-Cancer(R)-therapy now proven 
- Growing investor interest in Nanostart and its portfolio companies 

Frankfurt - November 4, 2009 - Marco Beckmann, CEO of Nanostart AG, the 
global nanotechnology investment company based in Frankfurt, will be 
presenting the company and its portfolio holdings to an audience of approx. 
80 selected investors and analysts on November 5 in New York City's 
Manhattan Club. 

The occasion for this special investor event is first and foremost the 
superb results of clinical trials reported by MagForce Nanotechnologies AG 
(ISIN DE000A0HGQF5), which is 77% owned by Nanostart. On November 3, 
MagForce announced the successful completion of its clinical trials 
demonstrating the efficacy of its Nano-Cancer(R) therapy in treating 
recurrent glioblastoma, a particularly malignant form of brain tumor. The 
median survival time was more than doubled in the patient group, far in 
excess of the study objective. These clinical trials thus conclusively 
demonstrated the efficacy of Nano-Cancer(R) therapy. The study also 
confirmed that the therapy is extremely well tolerated by patients compared 
to conventional therapies, with no significant side effects. 

The presentation will take place as part of an evening program. Marco 
Beckman will be in the spotlight as the event's sole speaker, and guests 
will have ample time following the formal presentation to speak 
individually with him and to ask detailed questions. 

Vanessa Mieschke, responsible for investor relations at Nanostart, 
commented: 'With these superb results from its clinical trials, our 
majority-owned MagForce is entering into a new era. Large U.S. investors 
have been awaiting these results with anxious anticipation.' 


About Nanostart: 
Nanostart AG is the world's leading nanotechnology investment company. The 
Frankfurt-based company provides venture capital financing for 
nanotechnology companies in various growth phases. It also provides the 
benefits of its experience and expertise to developers of financial 
instruments and to investors in the nanotechnology sector. For further 
information about the company, please visit www.nanostart.de. 

Disclaimer: 
This notice constitutes neither an offer to sell nor a solicitation of 
offers to purchase or subscribe to securities. There will be no public 
offering of securities of Nanostart AG in conjunction with the existing 
listing of its shares in the 'Entry Standard' segment of the regulated 
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This 
notice does not constitute a securities prospectus. Neither this notice nor 
the information contained within is intended for direct or indirect 
distribution within the United States of America, Canada, Australia or 
Japan. 

Media contact: 
Nanostart AG 
Public Relations 
Dr. Hans Joachim Dürr 
Goethestrasse 26-28 
D-60313 Frankfurt 
Germany 
phone: +49 (0)69-21 93 96 111 
fax: +49 (0)69-21 93 96 122 
e-mail: presse@nanostart.de 




04.11.2009  Financial News transmitted by DGAP